Physicians' Academy for Cardiovascular Education

PCSK9

UP TO DATE: Follow news, literature and expert perspectives on PCSK9 inhibition in lipid management

Effects of intensive lipid lowering on coronary plaque characteristics

10' education - Oct. 24, 2022 - Prof. Lorenz Räber, MD, PhD & Prof. Stephen Nicholls, MD

The spectrum of therapeutic options: which therapies to consider?

10' education - Oct. 18, 2022 - Prof. Ulf Landmesser, MD

Real world evidence with PCSK9i mAb; implications and lessons for current clinical use

10' education - Oct. 12, 2022 - Raul Santos, MD, PhD & Prof. Maciej Banach, MD, PhD

The clinical challenge: a patient with multiple risk factors

10' education - Oct. 7, 2022 - Prof. Erik Stroes, MD, PhD

Targeting the PCSK9 pathway: where do novel therapies fit in?

10' education - Oct. 5, 2022 - Ann Marie Navar, MD, PhD

Changing paradigms in LDL-c reduction

10' education - Sep. 28, 2022 - Prof. Kausik Ray, MD

Novel LDL-c lowering therapies: What is the potential for ANGPTL3 inhibition in HoFH?

10' education - July 25, 2022 - Prof. Frederick Raal, MD, PhD

Optimizing treatment for patients with HoFH

10' education - July 13, 2022 - Prof. Erik Stroes, MD, PhD

PCSK9i reduces plaque burden in coronary arteries

3' education - Apr. 6, 2022 - Prof. Lorenz Räber, MD, PhD
Experts in dialogue - LDL-c goal attainment in high risk patients

What are current challenges and barriers in achieving LDL-c goals?

15' education - Apr. 13, 2021 - Prof. Lale Tokgözoğlu, MD and prof. Kausik Ray, MD - Online CME
Experts in dialogue - LDL-c goal attainment in high risk patients

The gap between guideline LDL-c goals and current practice: How are we doing?

15' education - Apr. 1, 2021 - Prof. François Mach, MD and prof. Erik Stroes, MD, PhD - Online CME
Experts in dialogue - LDL-c goal attainment in high risk patients

The proven case for LDL-c lowering

15' education - Mar. 26, 2021 - Prof. Kausik Ray, MD and prof. John Kastelein, MD, PhD

Introduction: PCSK9i & LDL-c - Guidelines, Practice & Innovation

10' education - Nov. 9, 2020 - Prof. John Kastelein, MD

Time to reduce implementation gaps of lipid-lowering therapy

10' education - Nov. 6, 2020 - Prof. Kausik Ray, MD - Online CME

Is there a role for PCSK9 inhibition in patients with high Lp(a)?

10' education - Nov. 2, 2020 - Prof. Vera Bittner, MD - Online CME

A novel small binding protein that targets PCSK9

3' education - Oct. 6, 2020 - Prof. Evan Stein, MD, PhD

Small interfering RNA against PCSK9 reduces LDL-c in HeFH independent of genotype

3' education - Oct. 6, 2020 - Prof. Frederick Raal, MD

Five years of PCSK9i - Lessons from practice: Which patients benefit most?

10' education - Sep. 30, 2020 - Prof. Erik Stroes, MD - Online CME

Updates in the 2019 ESC/EAS guidelines for the management of dyslipidemia

10' education - Sep. 29, 2020 - Prof. François Mach, MD

One year after the new ESC/EAS dyslipidemia guidelines

10' education - Sep. 17, 2020 - Prof. François Mach - Online CME

Treatment goals for LDL-c-lowering and emerging evidence for the importance of Lp(a)

10' education - May 26, 2020 - Prof. J. Wouter Jukema, MD - Leiden, The Netherlands

One step closer to controlling LDL-c levels in HoFH with PCSK9i

3' education - Apr. 9, 2020 - Dirk Blom, PhD

Addressing lipid risk: a system-wide approach to implementation

5' education - Feb. 27, 2020 - Jorge Plutzky, MD

Patient-reported cognition at the end of a PCSK9 antibody trial

5' education - Nov. 17, 2019 - Baris Gencer, MD

Translating ESC/EAS Dyslipidemia Guidelines to clinical practice

10' education - Feb. 18, 2020 - Prof. Kausik Ray, MD

Treatment benefit with PCSK9 antibody in patients with recent vs. remote MI

5' education - Feb. 2, 2020 - Baris Gencer, MD

Translating pathophysiological, genetic and trial data to practical LDL-c treatment recommendations

10' education - Dec. 19, 2019 - Professor Ulrich Laufs, MD, PhD

Rationale of new recommendations in ESC/EAS Guidelines for Dyslipidemia

10' education - Dec. 19, 2019 - Prof. Ulf Landmesser, MD

LDL-c, atherosclerotic plaques and CV risk - what to do about it

10' education - Jan. 14, 2020 - Prof. Thomas Lüscher, MD

PCSK9 siRNA, on top of maximally tolerated statin therapy, potently lowers LDL-c

3' education - Nov. 16, 2019 - R. Scott Wright, MD, Rochester, MN, USA - AHA 2019, Philadelphia

A decade of innovation, guidelines, and paradigm shifts in LDL-c management

Accredited e-Learning

Online-CME - This course consists of 3 parts.
This course consists of 3 parts.

The goal of LDL-c management is to reduce long-term CVD risk. Statins form the foundation of lipid-lowering therapy, but more ammunition is needed to attain LDL-c goals in all patients. This series of 3 presentations discusses current and evolving therapeutic LDL-c lowering options.

Efficacy and safety of PCSK9 siRNA in primary prevention cohort

Literature - Nov. 23, 2022 - Ray KK, et al. - Eur Heart J. 2022

In an ORION-11 substudy, inclisiran reduced LDL-c, non-HDL-c and apoB levels in a subgroup of high-risk patients with elevated LDL-c but without prior CV events receiving maximally tolerated statin therapy.

Potential CV benefits of PCSK9 siRNA in high-risk patients with elevated LDL-c

Literature - Nov. 15, 2022 - Ray KK, et al. - Eur Heart J. 2022

A pooled analysis of ORION-9, -10 and -11 offers early insights into the potential of inclisiran to lower CV risk in high-risk patients with elevated LDL-c levels, while results of dedicated CV outcomes trials are awaited.

Sustained LDL-c lowering with PCSK9 siRNA up to 4 years

News - Nov. 10, 2022

AHA 2022 High CV risk patients in ORION-1 were invited to participate in open-label extension study with inclisiran -the ORION-3 study. What is the 4-year long-term efficacy and safety of inclisiran in these patients?

PCSK9i does not negatively influence cognitive functioning in children with HeFH

Literature - Oct. 24, 2022 - Gaudet D, et al. - J Clin Lipidol. 2022

RCTs among adults with HeFH show that treatment with evolocumab does not lead to cognitive dysfunction. But does the same hold true for pediatric patients with HeFH? This post-hoc analysis of data from the HAUSER-RCT study offers more insight.

Effects of intensive lipid lowering on coronary plaque characteristics

10' education - Oct. 24, 2022 - Prof. Lorenz Räber, MD, PhD & Prof. Stephen Nicholls, MD
Prof. Räber and Prof. Nicholls discuss the results and implications of the PACMAN-AMI study, that investigated the effect of PCSK9i alirocumab on top of high-intensity statins on coronary plaque characteristics in patients with acute MI.

Prof. Räber and Prof. Nicholls discuss the results and implications of the PACMAN-AMI study, that investigated the effect of PCSK9i alirocumab on top of high-intensity statins on coronary plaque characteristics in patients with acute MI.

The spectrum of therapeutic options: which therapies to consider?

10' education - Oct. 18, 2022 - Prof. Ulf Landmesser, MD
What are the current and potential future options in the precision management of patients with atherosclerotic cardiovascular disease? Prof. Landmesser presents these options per segment.

What are the current and potential future options in the precision management of patients with atherosclerotic cardiovascular disease? Prof. Landmesser presents these options per segment.

Real world evidence with PCSK9i mAb; implications and lessons for current clinical use

10' education - Oct. 12, 2022 - Raul Santos, MD, PhD & Prof. Maciej Banach, MD, PhD
Raul Santos and Maciej Banach talk about the safety of PCSK9 mAbs and of very low cholesterol levels, and discuss the importance of patient education to improve adherence.

Raul Santos and Maciej Banach talk about the safety of PCSK9 mAbs and of very low cholesterol levels, and discuss the importance of patient education to improve adherence.

Long-term PCSK9i treatment in pediatric HeFH patients safe and reduces LDL-c

Literature - Oct. 7, 2022 - Santos RD, et al. - Lancet Diabetes Endocrinol. 2022

The HAUSER-RCT study showed that in pediatric patients with HeFH, treatment with evolocumab for 24 weeks is safe and reduces LDL-c levels, compared with placebo. But what about the long-term safety and efficacy of evolocumab in this patient population?

The clinical challenge: a patient with multiple risk factors

10' education - Oct. 7, 2022 - Prof. Erik Stroes, MD, PhD
How can we make the best choices for optimal, affordable and sustainable care for patients with high CV risk due to multiple risk factors? Prof. Stroes illustrates the challenge of choosing.

How can we make the best choices for optimal, affordable and sustainable care for patients with high CV risk due to multiple risk factors? Prof. Stroes illustrates the challenge of choosing.

Targeting the PCSK9 pathway: where do novel therapies fit in?

10' education - Oct. 5, 2022 - Ann Marie Navar, MD, PhD
Where do novel therapies targeting the PCSK9 pathway might fit in with regard to the lipid management paradigm? Ann Marie Navar gives an overview on current and future therapies.

Where do novel therapies targeting the PCSK9 pathway might fit in with regard to the lipid management paradigm? Ann Marie Navar gives an overview on current and future therapies.

Changing paradigms in LDL-c reduction

10' education - Sep. 28, 2022 - Prof. Kausik Ray, MD
Prof. Ray explains why therapy for LDL-c lowering in very high-risk patients should become like BP-combination therapy.

Prof. Ray explains why therapy for LDL-c lowering in very high-risk patients should become like BP-combination therapy.

PCSK9